The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer

On 21 January 2021, the European Commission amended the marketing authorisation granted for pembrolizumab to include the first-line treatment of microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC) in adults. The recommended dose of pembroli...

Descripción completa

Detalles Bibliográficos
Autores principales: Trullas, A., Delgado, J., Genazzani, A., Mueller-Berghaus, J., Migali, C., Müller-Egert, S., Zander, H., Enzmann, H., Pignatti, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111576/
https://www.ncbi.nlm.nih.gov/pubmed/33940347
http://dx.doi.org/10.1016/j.esmoop.2021.100145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111576/
https://www.ncbi.nlm.nih.gov/pubmed/33940347
http://dx.doi.org/10.1016/j.esmoop.2021.100145

Ejemplares similares